194 results
8-K
INCY
Incyte Corp.
12 Jan 15
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
12:00am
and commercialization rights to four checkpoint modulators directed against GITR, OX40, LAG-3 and TIM-3. In addition to the initial four program targets, the Company … and Agenus have the option to jointly nominate and pursue additional targets within the framework of the collaboration. These targets may be designated
8-K
EX-99
INCY
Incyte Corp.
8 Feb 99
Current report
12:00am
Investor Relations
(650) 845-4515 (650) 845-4589
INCYTE REPORTS YEAR-END RESULTS AND 1999 FINANCIAL TARGETS … , and not incur
the complexity and administrative costs associated with a tracking stock
vehicle."
1999 TARGETS
- -------------
The following
8-K
EX-99.1
INCY
Incyte Corp.
8 Sep 03
Other events
12:00am
that targets the HIV-1 and HIV-2 reverse transcriptase. Preclinical studies indicate that Reverset inhibits replication of wild type and mutant strains … and intellectual property has become increasingly valuable for the identification of new research targets and to the discovery and development of new drugs
8-K
EX-99.1
INCY
Incyte Corp.
12 Jan 15
Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies
12:00am
targets available to us, and strengthens our ability to identify and advance novel therapeutic combinations,” said Hervé Hoppenot, President and CEO … , the parties have an option to jointly nominate and pursue additional targets within the framework of the multi-year collaboration. Terms also include
8-K
EX-99.1
g28iqon0ioeg fg8m9
30 Jul 03
Incyte Reports Second Quarter 2003 Financial Results
12:00am
8-K
uusjmfxi43
22 Feb 00
Current report
12:00am
8-K
y2vp2u9wc yt2
8 Feb 99
Current report
12:00am
8-K
EX-99.1
7jjky ydkxdy56
25 Jul 00
Current report
12:00am